Monographie - Scopolamine N-butyl bromide

Ostatnia aktualizacja :
19/11/2024

Scopolamine N-butyl bromide

Struktura chemiczna

Nazwa handlowa

Trade names are indicative and excipients composition can be different depending on the country and manufacturers

Buscapina	Hiszpania
Buscolysin	Polska
Buscopan	Australia, Austria, Belgia, Brazylia, Egipt, Finlandia, Holandia, Islandia, Kanada, Luksemburg, Niemcy, Norwegia, nowa Zelandia, Portugalia, Szwajcaria, Szwecja, Tunisie, Turcja, Zjednoczone Emiraty Arabskie
Butilbromuro de hioscina	Argentyna, KolumbiaKolumbia
Cifespasmo	Argentyna
Colobolina	Argentyna
Dolopina	Ekwador
Escopolamina N butyl bromuro	Chile
Hiocin	Wenezuela
Hioscina	Argentyna, KolumbiaKolumbia, Peru
Hioscina butil bromuro	KolumbiaKolumbia, Peru
Hyocidic	Iran
Hyoscine	Australia
Hyoscine hydrobromide	Kanada
Hyotex	Iran
Pasmodina Drawer	Argentyna
Rupe N	Argentyna
Scoburen	Francja
Selpirans	Wenezuela
Spasmopan	Tunisie
Xemol	Turcja

Bibliografia : Scopolamine N-butyl bromide

	typ	publikacja
1230	Czasopismo	Regnard C, Pashley S, Westrope F. Anti-emetic / diamorphine mixture compatibility in infusion pumps. Br J Pharm Pract 1986 ; 8: 218-220.
1232	Czasopismo	Beatson C, Taylor A. A physical compatibility study of furosemide & flucloxacillin injections. Br J Pharm Pract 1987 ; 9: 223-226, 236.
1405	Czasopismo	Peterson GM, Miller KA, Galloway JG, Dunne PF. Compatibility and stability of fentanyl admixtures in polypropylene syringes. J Clin Pharm Ther 1998 ; 23: 67-72.
1757	Czasopismo	Schrijvers D, Tai-Apin C, De Smet MC, Cornil P, Vermorken JB, Bruyneel P. Determination of compatibility and stability of drugs used in palliative care. J Clin Pharm Ther 1998 ; 23: 311-314.
1847	Czasopismo	Anacardo R, Perilli O, Bartolini S, Gentile MM, Mazzeo P, Carlucci G. Physicochemical compatibility between ketoprofen kysine salt injections (Artrosilene®) and pharmaceutical products frequently used for combined therapy by intravenous administration. J Pharm Biomed Anal 2003 ; 32, 6: 1235-1241.
1966	Czasopismo	Barcia E, Reyes R, Azuara L, Sànchez Y, Negro S. Stability and compatibility of binary mixtures of morphine hydrochloride with hyoscine-n-butyl bromide. Support Care Cancer 2005 ; 13, 4: 239-245.
1970	Czasopismo	Barcia E, Reyes R, Azuara M.L, S?nchez Y, Negro S. Compatibility of haloperidol and hyoscine-N-butyl bromide in mixtures for subcutaneous infusion to cancer patients in palliative care. Support Care Cancer 2003 ; 11, 2: 107-113.
1971	Czasopismo	Azuara ML, Sanchez Y, Reyes R, Barcia E. Physical compatibility and in vivo evaluation of drug mixtures forsubcutaneous infusion to cancer patients in palliative care. Support Care Cancer 2001
2055	Czasopismo	Negro S, Reyes R, Azuara ML, Sanchez Y, Barcia E. Morphine, haloperidol and hyoscine N-butyl bromide combined in sc infusion solutions : compatibility and stability evaluation in terminal oncology patients. Int J Pharm 2006 ; 307: 278-284.
2125	Czasopismo	Gardiner PR. Compatibility of an injectable oxycodone formulation with typical diluents, syringes, tubings, infusion bags and drugs for potential co-administration. Hospital Pharmacist 2003 ; 10: 354-361.
2176	Czasopismo	Barcia E, Martin A, Azuara ML, Sanchez Y, Negro S. Tramadol and hyoscine N-butyl bromide combined in infusion solutions: compatibility and stability. Support Care Cancer 2007 ; 15: 57-62.
2900	Czasopismo	Hines S, Pleasance S. Compatibility of an injectable high strength oxycodone formulation with typical diluents, syringes, tubings,infusion bags and drugs for potential co-administration. EJHP 2009 ; 15, 5: 32-38.
3132	Czasopismo	Negro S, Martin A, Azuara L, Sanchez Y, Barcia E. Compatibility and stability of ternary admixtures of tramadol, haloperidol, and hyoscine. J Palliat Med 2010 ; 13, 3: 273-277.
4404	plakat	Müller U, Haller F, Wiedemeier P, Steuer C. Compatibility studies of seven commonly used drugs for parenteral administration in palliative care. JFSPH 2019 2019

Mentions Légales